<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605991</url>
  </required_header>
  <id_info>
    <org_study_id>17428</org_study_id>
    <secondary_id>I8B-MC-ITSW</secondary_id>
    <nct_id>NCT04605991</nct_id>
  </id_info>
  <brief_title>A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)</brief_title>
  <official_title>A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate glycemic control in participants with type 2 diabetes&#xD;
      who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.&#xD;
      Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system)&#xD;
      during the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">February 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Percentage of Time with CGM Glucose Values between 70-180 milligrams/deciliter (mg/dL) (3.9-10.0 millimoles/Liter [mmol/L]) (both inclusive) during Daytime Period with 14 Days of CGM Use</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Percentage of Time with CGM Glucose Values between 70-180 mg/dL (3.9-10.0 mmol/L) (both inclusive) during Daytime Period with 14 Days of CGM Use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Percentage of Time with CGM Glucose Values between 70-180 mg/dL (3.9-10.0 mmol/L) (both inclusive) during the 24-hour Period with 14 Days of CGM Use</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Percentage of Time with CGM Glucose Values between 70-180 mg/dL (3.9-10.0 mmol/L) (both inclusive) during the 24-hour Period with 14 Days of CGM Use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Percentage of Time with CGM Glucose Values &lt;54 mg/dL (&lt;3.0 mmol/L) during Daytime and 24-hour Periods with 14 Days of CGM Use</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Percentage of Time with CGM Glucose Values &lt;54 mg/dL (&lt;3.0 mmol/L) during Daytime and 24-hour Periods with 14 Days of CGM Use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Percentage of Time with Sensor Glucose Values &gt;180 mg/dL (&gt;10.0 mmol/L) and &gt;250 mg/dL (&gt;13.9 mmol/L), during Daytime and 24- Hour Periods with 14 Days of CGM Use</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Percentage of Time with Sensor Glucose Values &gt;180 mg/dL (&gt;10.0 mmol/L) and &gt;250 mg/dL (&gt;13.9 mmol/L), during Daytime and 24- Hour Periods with 14 Days of CGM Use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Postprandial Incremental Area Under the Curve (AUC)₀-₁ Hour, obtained from CGM use</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Postprandial Incremental AUC₀-₁ Hour, obtained from CGM use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Postprandial Incremental AUC₀-₂ Hour, obtained from CGM use</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Postprandial Incremental AUC₀-₂ Hour, obtained from CGM use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HbA1c &lt;7% and ≤6.5%</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of Participants with HbA1c &lt;7% and ≤6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Bolus Insulin Dose</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Bolus Insulin Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Basal Insulin Dose</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Basal Insulin Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Insulin Dose</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Total Insulin Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Bolus/Total Insulin Dose Ratio</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in Bolus/Total Insulin Dose Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Glycemic Control Domain Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from Baseline in ITSQ Glycemic Control Domain Scores</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>LY900014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900014 given via subcutaneous (SC) injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants diagnosed (clinically) with type 2 diabetes mellitus (T2D) for at least 1&#xD;
             year prior to screening.&#xD;
&#xD;
          -  Have been treated with basal-bolus multiple daily injection (MDI) therapy for at least&#xD;
             90 days prior to screening including:&#xD;
&#xD;
               -  Basal insulin glargine U-100, in combination with bolus insulin analog (insulin&#xD;
                  lispro, insulin aspart, or insulin glulisine) with meals.&#xD;
&#xD;
               -  Participant must have been treated with the same type of allowed bolus insulin&#xD;
                  analog for at least 30 days prior to screening.&#xD;
&#xD;
          -  Participants may be treated with up to 3 of the following oral antihyperglycemic&#xD;
             medications (OAMs) for T2D in accordance with local regulations:&#xD;
&#xD;
               1. Metformin&#xD;
&#xD;
               2. Dipeptidyl peptidase-4 (DPP-4) inhibitor&#xD;
&#xD;
               3. sodium glucose cotransporter 2 (SGLT2) inhibitor&#xD;
&#xD;
               4. oral glucagon-like peptide 1 (GLP-1) agonist&#xD;
&#xD;
          -  Doses of OAMs are required to have been stable for at least 90 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Participants may be treated with injectable GLP-1 receptor agonist for T2D in&#xD;
             accordance with local regulations. The GLP-1 receptor agonist dose is required to have&#xD;
             been stable for at least 90 days prior to screening.&#xD;
&#xD;
          -  Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have been diagnosed at any time with type 1 diabetes mellitus or latent autoimmune&#xD;
             diabetes in adults.&#xD;
&#xD;
          -  Have had any episode of severe hypoglycemia (defined as requiring assistance due to&#xD;
             neurologically disabling hypoglycemia) within 6 months prior to screening.&#xD;
&#xD;
          -  Have had any episode of hyperglycemic hyperosmolar state or diabetic ketoacidosis&#xD;
             within 6 months prior to screening.&#xD;
&#xD;
          -  Have hypoglycemia unawareness as judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Muir Physician Network Clinical Research Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valley Endocrine, Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Investigators, Inc.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Centre</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CMR of Greater New Haven</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Encore Medical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Coast Clinical Research, Inc</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute, Inc.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research at The Jones Center</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes and Endocrinology Research Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maryland Cardiovascular Specialists</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endocrine and Metabolic Consultants</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Research Center Tenaya</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Research Center Tenaya</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research NYC, Inc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suny Health Science Center at Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cataret Medical Group</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intend Research, LLC</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-334-3505</phone>
    </contact>
    <investigator>
      <last_name>Tira Chaicha- Brom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endocrine Ips, Pllc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consano Clinical Research, LLC</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Burke Internal Medicine and Research</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, LLC</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manati Center for Clinical Research Inc</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1o3M94i5GGiiJPY7Q2RZBo</url>
    <description>A Study of Mealtime Insulin LY900014 in Participants with Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)</description>
  </link>
  <verification_date>November 2, 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

